Balance Sheet
Cash Flow Statement
Amortizatization of IntangiblesCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Account PayablesChange in Accured ExpensesChange in Acquisitions & DivestmentsChange in CashDepreciation & Amortization (CF)Free Cash FlowGains from Investment SecuritiesNet Cash FlowNet IncomeShare-based CompensationShares Issued
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Nurix Therapeutics (NRIX) Cash from Investing Activities: 2019-2025

Historic Cash from Investing Activities for Nurix Therapeutics (NRIX) over the last 6 years, with Aug 2025 value amounting to $50.5 million.

  • Nurix Therapeutics' Cash from Investing Activities rose 336.54% to $50.5 million in Q3 2025 from the same period last year, while for Aug 2025 it was $6.7 million, marking a year-over-year increase of 105.10%. This contributed to the annual value of -$257.7 million for FY2024, which is 477.32% down from last year.
  • Per Nurix Therapeutics' latest filing, its Cash from Investing Activities stood at $50.5 million for Q3 2025, which was down 29.40% from $71.5 million recorded in Q2 2025.
  • In the past 5 years, Nurix Therapeutics' Cash from Investing Activities ranged from a high of $71.5 million in Q2 2025 and a low of -$140.8 million during Q4 2024.
  • In the last 3 years, Nurix Therapeutics' Cash from Investing Activities had a median value of $22.8 million in 2023 and averaged -$3.8 million.
  • As far as peak fluctuations go, Nurix Therapeutics' Cash from Investing Activities slumped by 2,344.78% in 2021, and later spiked by 1,777.04% in 2022.
  • Quarterly analysis of 5 years shows Nurix Therapeutics' Cash from Investing Activities stood at -$36.5 million in 2021, then surged by 250.61% to $55.0 million in 2022, then tumbled by 126.13% to -$14.4 million in 2023, then tumbled by 879.73% to -$140.8 million in 2024, then spiked by 336.54% to $50.5 million in 2025.
  • Its Cash from Investing Activities stands at $50.5 million for Q3 2025, versus $71.5 million for Q2 2025 and $25.5 million for Q1 2025.